| James A Siskosky, DO | |
|
4200 Whitehall Dr, Ste 150, Ann Arbor, MI 48105-9694 | |
| (734) 995-0308 | |
| (734) 995-0425 |
| Full Name | James A Siskosky |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Occupational Medicine |
| Location | 4200 Whitehall Dr, Ann Arbor, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962523308 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083X0100X | Preventive Medicine - Occupational Medicine | 5101006444 (Michigan) | Primary |
| Entity Name | Iha Health Services Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457408965 PECOS PAC ID: 2466351440 Enrollment ID: O20040108000355 |
News Archive
In findings that should finally put to rest a decade of controversy in the field of neurobiology, a team at The Scripps Research Institute has found decisive evidence that a specific neurotransmitter system-the endocannabinoid system-is active in a brain region known to play a key role in the processing of memory, emotional reactions, and addiction formation. The new study also shows that this system can dampen the effects of alcohol, suggesting an avenue for the development of drugs to combat alcohol addiction.
Increased stress levels, sleep disorders and obesity have become hallmarks of present lifestyle. These conditions are often correlated with serious health problems such as cancer, diabetes, cerebral ischemia, stroke, etc.
A decline in contributions from the WHO's leading 30 "traditional" donor nations and the exchange rate for the weaker U.S. dollar are causing the agency to cut its budget and staff, WHO Director-General Margaret Chan told reporters in a news conference at the World Health Assembly in Geneva on Tuesday, the Associated Press reports.
Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.
› Verified 1 days ago
| Entity Name | First Choice Urgent Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629201264 PECOS PAC ID: 9739221912 Enrollment ID: O20100126000872 |
News Archive
In findings that should finally put to rest a decade of controversy in the field of neurobiology, a team at The Scripps Research Institute has found decisive evidence that a specific neurotransmitter system-the endocannabinoid system-is active in a brain region known to play a key role in the processing of memory, emotional reactions, and addiction formation. The new study also shows that this system can dampen the effects of alcohol, suggesting an avenue for the development of drugs to combat alcohol addiction.
Increased stress levels, sleep disorders and obesity have become hallmarks of present lifestyle. These conditions are often correlated with serious health problems such as cancer, diabetes, cerebral ischemia, stroke, etc.
A decline in contributions from the WHO's leading 30 "traditional" donor nations and the exchange rate for the weaker U.S. dollar are causing the agency to cut its budget and staff, WHO Director-General Margaret Chan told reporters in a news conference at the World Health Assembly in Geneva on Tuesday, the Associated Press reports.
Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James A Siskosky, DO 24 Frank Lloyd Wright Dr, J2000, Ann Arbor, MI 48105-9484 Ph: (734) 747-6766 | James A Siskosky, DO 4200 Whitehall Dr, Ste 150, Ann Arbor, MI 48105-9694 Ph: (734) 995-0308 |
News Archive
In findings that should finally put to rest a decade of controversy in the field of neurobiology, a team at The Scripps Research Institute has found decisive evidence that a specific neurotransmitter system-the endocannabinoid system-is active in a brain region known to play a key role in the processing of memory, emotional reactions, and addiction formation. The new study also shows that this system can dampen the effects of alcohol, suggesting an avenue for the development of drugs to combat alcohol addiction.
Increased stress levels, sleep disorders and obesity have become hallmarks of present lifestyle. These conditions are often correlated with serious health problems such as cancer, diabetes, cerebral ischemia, stroke, etc.
A decline in contributions from the WHO's leading 30 "traditional" donor nations and the exchange rate for the weaker U.S. dollar are causing the agency to cut its budget and staff, WHO Director-General Margaret Chan told reporters in a news conference at the World Health Assembly in Geneva on Tuesday, the Associated Press reports.
Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.
› Verified 1 days ago
Jeffrey Evans Terrell, MD Preventive Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Dr. Arthur Oleinick, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 2016 Vinewood Blvd, Ann Arbor, MI 48104 Phone: 734-665-7693 | |
Joseph Valle, MD Preventive Medicine Medicare: Accepting Medicare Assignments Practice Location: 3131 S State St, Ann Arbor, MI 48108 Phone: 734-213-6285 Fax: 734-213-6482 | |
Matthew L Boulton, MD, MPH Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 1415 Washington Hts, Ann Arbor, MI 48109 Phone: 734-936-1623 | |
David Gulapa Paje, M.D. Preventive Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Dr. James P Bagian, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 24 Frank Lloyd Wright Dr Lbby M, Ann Arbor, MI 48105 Phone: 734-930-5920 Fax: 734-930-5877 | |
Jennifer Marie Mcdonald, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 380 Parkland Plaza, Floor 1 Suite 110, Ann Arbor, MI 48103 Phone: 734-998-7380 |